Travaux publiés

Publications (2005 au présent)

(Les liens vers les sites externes s'ouvriront dans une nouvelle fenêtre)

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial
Annals of the Rheumatic Diseases 2010;69(1):222-5.
Kekow J, Moots R, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics
Journal of the European Academy of Dermatology and Venereology 2009
Christophers E, Barker JNWN, Griffiths CEM, Dauden E, Milligan G, Molta C, Sato R, Boggs R

The ISPOR Good Practices for Quality Improvement of Cost-effectiveness Research Task Force Report
Value in Health 2009;12(8)
McGhan WF, Maiwenn A, Doshi JA, Kamae I, Marx SE, Rindress D

Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence
International Wound Journal 2009;6(5):386-93.
Moffatt C, Kommala D, Dourdin N, Choe Y

Cost-effectiveness of atorvastatin 10 mg daily in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada
Canadian Journal of Diabetes 2009;33(4):363-74.
Khoury H, Wagner M, Merikle E, Johnson SJ, Roberts C

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions
Vaccine 2009;27(36):4891-904.
Ogilvie I, El Khoury A, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
Arthritis & Rheumatism 2009;61(11):1592-600.
Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, vanVollenhoven RF

Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada
Canadian Journal of Clinical Pharmacology 2009;16(2):e331-e345.
Wagner M, Goetghebeur M, Pandya A, Merikle E, Chu P, Taylor DCA

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
Canadian Journal of Cardiology 2009;25(11):e362-e369.
Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B

Worksite health promotion: the value of the Tune Up Your Heart program
Population Health Management 2009;12(6):297-304.
Chung M, Melnyk P, Blue D, Renaud D, Breton M-C

Detection of Cognitive Impairment and Dementia Using the Animal Fluency Test: the DECIDE Study
Canadian Journal of Neurological Sciences 2009;36(5):599-604.
Sebaldt RJ, Dalzeil W, Massoud F, Tanguay A, Ward R, Thabane L, Melnyk P, Landry P, Lescrauwaet B

Post-marketing surveillance of the safety and effectiveness of etanercept in Japan
Journal of Rheumatology 2009:36(5);898-906
Koike T, Harigai M, Inokuma S, Ishiguro N, Inoue K, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M

A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in southwestern Ontario, Canada
Clinical Therapeutics 2008;30(6):1145-54.
Petrella RJ, Merikle E

Chronic myeloid leukemia in Asia
International Journal of Hematology 2008;89(1):14-23.
Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim D-W, Kweon I-Y, O'Neil WM, Saikia TK, Wang J

Limitations of statin monotherapy for the treatment of dyslipidemia - a projection based on the Canadian Lipid Study Observational
Current Medical Research and Opinion 2008;25(1):47-55.
Senecal M, Fodor G, Gagné C, Genest J, Lavoie M-A, McPherson R, Marentette MA, Sebaldt RJ

Evidence and Value: Impact on DEcisionMaking - the EVIDEM framework and potential applications
BMC Health Services Research 2008;8:270.
Goetghebeur M, Wagner M, Khoury H, Levitt R, Erickson LJ, Rindress D

Fentanyl HCl iontophoretic transdermal system versus morphine IV-PCA for postoperative pain management: survey of healthcare provider opinion
Current Medical Research and Opinion 2008;25(2):293-301.
Bonnet F, Eberhart L, Wennberg E, Dodds S, VanBellinghen L, Annemans L, Kavanaugh S, Choe Y

Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study
(includes editorial )
Canadian Respiratory Journal 2008;15(1):13-9.
Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A, Hernandez P, Rouleau M, Petrie A, Foster G, Thabane L, Haddon J, Scalera A

Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based study
Canadian Journal of Infectious Disease and Medical Microbiology 2008;19(6):397-404.
Senecal M, Brisson M, the MIRAGE (Measuring the Impact of Rotavirus-Associated Gastroenteritis Episodes) study group, Lebel MH, Yaremko J, Wong R, Gallant L, Garfield HA, Abelman DJ, Ward RL, Sampalis J, Mansi JA

Burden of illness of neovascular age-related macular degeneration in Canada
Canadian Journal of Ophthalmology 2007;42(6):836-43.
Cruess A, Zlateva G, Xu X, Rochon S

Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population
Social Psychiatry & Psychiatric Epidemiology 2007 Sep;42(9):690-7.
Harley C, Li H, Corey-Lisle.P., L'Italien GJ, Carson W

A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets
Clin Ther 2007;29(3):519-28.
Lachaine J, Merikle E, Tarride JE, Montpetit M, Rinfret S

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
Rheumatology (Oxford) 2007;49(6):999-1004.
Braun J, McHugh N, Singh A, Wajdula JS, Sato R

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
Cancer 2007;110(3):499-508.
Risebrough NA, Verma S, Trudeau M, Mittman N

Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis
Clin Ther 2007;29(4):742-50.
Petrella RJ, Merikle E, Jones J

Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer
Breast Cancer Res Treat 2007;101(1):37-49.
El Ouagari K, Karnon J, Delea TE, Talbot W, Brandman JB

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial
Annals for Rheumatic Disease 2008;67(8):1104-1110.
van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A

Patient reported outcomes and health-related quality of life in effectiveness studies: pros and cons
Drug Development Research. 2007;67(3):193-201.
Marquis P, Acquadro C, Roberts M.

Methicillin-resistant staphylococcus aureus: a public health issue with economic consequences
Canadian Journal of Infectious Disease and Medical Microbiology. 2007;18(1):27-34.
Goetghebeur M, Landry A, Han D, Vicente C

Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study
Rheumatology (Oxford) 2007;46(2):265-72.
Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN

Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs
Drug Safety. 2006;29(7):613-20.
Barnard L, Lavoie D, Lajeunesse.N

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis
Modern Rheumatology. 2006;16(2):77-84.
Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, et al.

Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats
Oligonucleotides. 2006;16(3):203-12.
Fortin M, Ferrari N, Higgins ME, Seguin S, Allam M, Allakhverdi Z, et al.

Evidence of Cost Shifting In California Hospitals
Health Affairs 2006;25(1):197-203.
Zwanziger J, Bamezai A

Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or nonselective nonsteroidal anti-inflammatory drugs in Quebec, Canada
Rheumatology (Oxford) 2006;45(7):903-10.
Rahme E, Toubouti Y, Hunsche E

Utilization and cost comparison of current and optimal prescribing of nonsteroidal anti-inflammatory drugs in Quebec, Canada
Journal of Rheumatology 2006;33(3):588-96.
Rahme E, Toubouti Y, LeLorier J

Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis
Arthritis & Rheumatism 2006;55(2):287-93.
Moreland LW, Genovese MC, Sato R, Singh A

Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Arthritis & Rheumatism 2006;55(1):27-34.
Rahme E, Hunsche E, Toubouti Y, Chabot I

Patient-reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial
Annals of Rheumatic Diseases 2006;65(3):328-34.
van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Pedersen R, Freundlich B, Fatenejad S

Burden of atopic dermatitis in Canada
International Journal of Dermatology 2006;45(1):31-36.
Barbeau M, Lalonde H

Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study-Observational (CALIPSO)
Canadian Journal of Cardiology 2005;21(13):1187-93.
Bourgault C, Davignon J, Fodor G, Gagné C, Gaudet D, Genest J, Lavoie M-A, Leiter L, McPherson R, Senecal M, Marentette M, Sebaldt R

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril
American Heart Journal 2005;150:985.e1-985.e8.
Wagner M, Rindress D, Desjardins B, Meilleur M-C, Ducharme A, Tardif JC

Pharmacokinetics of proton pump inhibitors in children
Clin Pharmacokinet 2005;44(5):441-66. Review.
Litalien C, Théorêt Y, Faure C

Implementation and outcomes of commercial disease management programs in the United States:
the Disease Management Outcomes Consolidation Survey
Disease Management 2005;8(4):253-64
Fitzner K, Fox K, Schmidt J, Roberts M, Rindress D, Hay J

Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative
assessment of response to antipsychotics in patients with schizophrenia and schizoaffective
disorder
Psychiatry Research 2005;136:211-221.
Tandon R, DeVellis RF, Han J, Li H, Frangou S, Dursun S

Medicare coverage and reimbursement of outpatient prescription drugs in the US:
history, recent changes and outlook for the future
Applied Health Economics and Health Policy 2005;4(1):9-14.
Forrest S, Goetghebeur MM, Hay J

The value of medicines in Canada
Canadian Journal of Clinical Pharmacology 2005;12(1):e10-e21.
Han D, Wang E

Haut de page